Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1Neuroblastoma 1Multiple Endocrine Neoplasia 1Carcinoid Tumor 1Adrenal Gland Neoplasms 1

Interventions

Cyclophosphamide 6Isotretinoin 5thymoglobulin 4fludarabine phosphate 4fludarabine 4aldesleukin 4Topotecan 4Temozolomide 4Melphalan 4Irinotecan 4Etoposide 4ribociclib 3Thiotepa 3Interleukin-2 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Busulfan 3Bone Marrow Transplantation 3Antilymphocyte Serum 3temsirolimus 2omburtamab I-131 2dinutuximab 2Vincristine 2Tretinoin 2TPI-287 2Stem Cell Transplantation 2Rituximab 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neuroblastoma × (18F)GTP1 × Clear all
NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡